Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) CFO Alexis Desieno sold 25,118 shares of the business's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $3.43, for a total transaction of $86,154.74. Following the completion of the sale, the chief financial officer now owns 116,481 shares of the company's stock, valued at $399,529.83. The trade was a 17.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Alexis Desieno also recently made the following trade(s):
- On Wednesday, October 2nd, Alexis Desieno sold 7,487 shares of Cardlytics stock. The stock was sold at an average price of $3.08, for a total transaction of $23,059.96.
Cardlytics Stock Down 6.0 %
Shares of CDLX stock opened at $3.38 on Friday. Cardlytics, Inc. has a one year low of $2.89 and a one year high of $20.52. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18. The stock has a fifty day moving average price of $3.72 and a 200 day moving average price of $6.41. The stock has a market cap of $171.77 million, a P/E ratio of -0.55 and a beta of 1.61.
Cardlytics (NASDAQ:CDLX - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.18. The business had revenue of $67.06 million for the quarter, compared to analysts' expectations of $57.77 million. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The firm's revenue for the quarter was down 15.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. Analysts predict that Cardlytics, Inc. will post -1.72 earnings per share for the current year.
Analysts Set New Price Targets
Buffett Dumps $982 Million in BofA Stock—What Does He Know?
From Genesis Gold Group | Ad
Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.
Get your FREE, no-obligation Wealth Protection Guide now
Several brokerages have recently issued reports on CDLX. Northland Securities downgraded Cardlytics from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $7.00 to $5.00 in a research report on Friday, August 16th. Bank of America downgraded Cardlytics from a "neutral" rating to an "underperform" rating and dropped their price target for the stock from $4.00 to $3.50 in a research report on Thursday, August 15th. Craig Hallum raised Cardlytics from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, November 6th. Northland Capmk downgraded shares of Cardlytics from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 16th. Finally, Lake Street Capital cut shares of Cardlytics from a "buy" rating to a "hold" rating and cut their target price for the company from $18.00 to $5.00 in a research note on Thursday, August 8th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Cardlytics presently has an average rating of "Hold" and an average target price of $6.92.
Get Our Latest Research Report on Cardlytics
Institutional Trading of Cardlytics
Large investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in Cardlytics by 7.5% in the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company's stock valued at $3,371,000 after buying an additional 73,484 shares in the last quarter. Barclays PLC boosted its holdings in shares of Cardlytics by 223.9% in the 3rd quarter. Barclays PLC now owns 58,026 shares of the company's stock worth $186,000 after acquiring an additional 40,112 shares in the last quarter. Quadrature Capital Ltd bought a new stake in Cardlytics during the 3rd quarter worth approximately $63,000. RBF Capital LLC increased its holdings in Cardlytics by 311.9% during the 3rd quarter. RBF Capital LLC now owns 488,128 shares of the company's stock valued at $1,562,000 after purchasing an additional 369,620 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in Cardlytics by 56.0% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 317,644 shares of the company's stock valued at $1,016,000 after purchasing an additional 113,966 shares during the last quarter. 68.10% of the stock is currently owned by institutional investors.
Cardlytics Company Profile
(
Get Free Report)
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
